These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

163 related articles for article (PubMed ID: 25986166)

  • 1. Survival of vancomycin-intermediate Staphylococcus aureus on hospital surfaces.
    Zarpellon MN; Gales AC; Sasaki AL; Selhorst GJ; Menegucci TC; Cardoso CL; Garcia LB; Tognim MC
    J Hosp Infect; 2015 Aug; 90(4):347-50. PubMed ID: 25986166
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacodynamic activity of ceftobiprole compared with vancomycin versus methicillin-resistant Staphylococcus aureus (MRSA), vancomycin-intermediate Staphylococcus aureus (VISA) and vancomycin-resistant Staphylococcus aureus (VRSA) using an in vitro model.
    Zhanel GG; Voth D; Nichol K; Karlowsky JA; Noreddin AM; Hoban DJ
    J Antimicrob Chemother; 2009 Aug; 64(2):364-9. PubMed ID: 19454524
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Isolates with low-level vancomycin resistance associated with persistent methicillin-resistant Staphylococcus aureus bacteremia.
    Howden BP; Johnson PD; Ward PB; Stinear TP; Davies JK
    Antimicrob Agents Chemother; 2006 Sep; 50(9):3039-47. PubMed ID: 16940100
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Surveillance and evidence of contamination in hospital environment from meticillin and vancomycin-resistant microbial agents.
    Squeri R; Grillo OC; La Fauci V
    J Prev Med Hyg; 2012 Sep; 53(3):143-5. PubMed ID: 23362619
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Ceftaroline pharmacodynamic activity versus community-associated and healthcare-associated methicillin-resistant Staphylococcus aureus, heteroresistant vancomycin-intermediate S. aureus, vancomycin-intermediate S. aureus and vancomycin-resistant S. aureus using an in vitro model.
    Zhanel GG; Rossnagel E; Nichol K; Cox L; Karlowsky JA; Zelenitsky S; Noreddin AM; Hoban DJ
    J Antimicrob Chemother; 2011 Jun; 66(6):1301-5. PubMed ID: 21429940
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Characterization of a vancomycin intermediate-resistant Staphylococcus aureus isolated from a hospital.
    Mirani ZA; Jamil N
    J Coll Physicians Surg Pak; 2010 Aug; 20(8):558-9. PubMed ID: 20688028
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Methicillin-resistant Staphylococcus aureus with reduced susceptibility to vancomycin in Sanprasitthiprasong Hospital.
    Panomket P; Thirat S; Wanram S; Sranujit RP
    J Med Assoc Thai; 2014 Apr; 97 Suppl 4():S7-11. PubMed ID: 24851558
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy of ME1036 against meticillin-resistant Staphylococcus aureus and vancomycin-insensitive S. aureus in a model of haematogenous pulmonary infection.
    Yanagihara K; Ohnishi Y; Morinaga Y; Nakamura S; Kurihara S; Seki M; Izumikawa K; Kakeya H; Yamamoto Y; Yamada Y; Kohno S; Kamihira S
    Int J Antimicrob Agents; 2008 Nov; 32(5):401-4. PubMed ID: 18715761
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Reduced glycopeptide susceptibility in methicillin-resistant Staphylococcus aureus (MRSA).
    Appelbaum PC
    Int J Antimicrob Agents; 2007 Nov; 30(5):398-408. PubMed ID: 17888634
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clonal dissemination of meticillin-resistant and vancomycin-intermediate Staphylococcus aureus in a Taiwanese hospital.
    Hsueh PR; Lee SY; Perng CL; Chang TY; Lu JJ
    Int J Antimicrob Agents; 2010 Oct; 36(4):307-12. PubMed ID: 20685086
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Evaluation of different methods to recover meticillin-resistant Staphylococcus aureus from hospital environmental surfaces.
    Dolan A; Bartlett M; McEntee B; Creamer E; Humphreys H
    J Hosp Infect; 2011 Nov; 79(3):227-30. PubMed ID: 21742414
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Bacterial contamination of frequently touched objects in a tertiary care hospital of Pokhara, Nepal: how safe are our hands?
    Bhatta DR; Hamal D; Shrestha R; Hosuru Subramanya S; Baral N; Singh RK; Nayak N; Gokhale S
    Antimicrob Resist Infect Control; 2018; 7():97. PubMed ID: 30128144
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Methicillin-resistant Staphylococcus aureus heterogeneously resistant to vancomycin in a Turkish university hospital.
    Sancak B; Ercis S; Menemenlioglu D; Colakoglu S; Hasçelik G
    J Antimicrob Chemother; 2005 Sep; 56(3):519-23. PubMed ID: 16046461
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Recognition and management of infections caused by vancomycin-intermediate Staphylococcus aureus (VISA) and heterogenous VISA (hVISA).
    Howden BP
    Intern Med J; 2005 Dec; 35 Suppl 2():S136-40. PubMed ID: 16271057
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Relevance of vancomycin-intermediate susceptibility and heteroresistance in methicillin-resistant Staphylococcus aureus bacteraemia.
    Khatib R; Jose J; Musta A; Sharma M; Fakih MG; Johnson LB; Riederer K; Shemes S
    J Antimicrob Chemother; 2011 Jul; 66(7):1594-9. PubMed ID: 21525024
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Identification of the first vancomycin intermediate-resistant Staphylococcus aureus (VISA) isolate from a hospital in Portugal.
    Gardete S; Aires-De-Sousa M; Faustino A; Ludovice AM; de Lencastre H
    Microb Drug Resist; 2008 Mar; 14(1):1-6. PubMed ID: 18346009
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparative proteomics analyses reveal a potential biomarker for the detection of vancomycin-intermediate Staphylococcus aureus strains.
    Drummelsmith J; Winstall E; Bergeron MG; Poirier GG; Ouellette M
    J Proteome Res; 2007 Dec; 6(12):4690-702. PubMed ID: 17997515
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Peptide biomarker discovery for identification of methicillin-resistant and vancomycin-intermediate Staphylococcus aureus strains by MALDI-TOF.
    Lu JJ; Tsai FJ; Ho CM; Liu YC; Chen CJ
    Anal Chem; 2012 Jul; 84(13):5685-92. PubMed ID: 22762263
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Antibiotic susceptibility survey of blood-borne MRSA isolates in Japan from 2008 through 2011.
    Hanaki H; Cui L; Ikeda-Dantsuji Y; Nakae T; Honda J; Yanagihara K; Takesue Y; Matsumoto T; Sunakawa K; Kaku M; Tomono K; Fukuchi K; Kusachi S; Mikamo H; Takata T; Otsuka Y; Nagura O; Fujitani S; Aoki Y; Yamaguchi Y; Tateda K; Kadota J; Kohno S; Niki Y
    J Infect Chemother; 2014 Sep; 20(9):527-34. PubMed ID: 25066429
    [TBL] [Abstract][Full Text] [Related]  

  • 20. In vitro activity of oritavancin against community-associated methicillin-resistant Staphylococcus aureus (CA-MRSA), vancomycin-intermediate S. aureus (VISA), vancomycin-resistant S. aureus (VRSA) and daptomycin-non-susceptible S. aureus (DNSSA).
    Saravolatz LD; Pawlak J; Johnson LB
    Int J Antimicrob Agents; 2010 Jul; 36(1):69-72. PubMed ID: 20413274
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.